According to Beckley Psytech, the company has initiated a Phase 2a study of its BPL-003 intranasal dry powder 5-MeO-DMT for the treatment of moderate-to-severe treatment-resistant depression. Beckley Psytech recently reported results from a Phase 1 study showing a dose proportional PK profile for BPL-003; that study also found that any consciousness-altering effects caused by the nasal powder were short-lived.
The open label Phase 2a study, which is being conducted at King’s College Hospital and Hammersmith Medicines Research, is expected to enroll 12 patients who will each get a single dose of BPL-003 along with psychological support. Subjects will be followed for 12 weeks post-dose. The company said that it also expects to initiate a study of single-dose BPL-003 for the treatment of alcoholism in early 2023.
Beckley Psytech CEO Cosmo Feilding Mellen commented, “Conditions like treatment resistant depression have a devastating effect on people around the world, but they are sadly underserved when it comes to treatment opportunities. We are proud to be conducting rigorous scientific investigations into the therapeutic potential of novel, short-acting psychedelic compounds like BPL-003 to help people in urgent need and we are looking forward to dosing the first patient in the coming weeks. I would like to take this opportunity to thank not only our research partners at King’s and HMR for their support and collaboration, but also the many healthy volunteers and future patients that participate in our trials and are willing to contribute to our research program. We at Beckley Psytech are all single-mindedly focussed on the wellbeing of patients and are grateful for their willingness to participate in clinical research.”
Read the Beckley Psytech press release.
